Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

AGN-242428 in the Treatment of Plaque Psoriasis

ClinicalTrials.gov ID: NCT03339999

Public ClinicalTrials.gov record NCT03339999. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of AGN-242428 in adult participants with moderate to severe plaque-type psoriasis.

Study identification

NCT ID
NCT03339999
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Enrollment
24 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 14, 2017
Primary completion
Mar 21, 2018
Completion
Apr 19, 2018
Last update posted
Apr 5, 2021

2017 – 2018

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
Total Skin and Beauty Dermatology Center, PC Birmingham Alabama 35205
Radiant Tucson Tucson Arizona 85712
Johnson Dermatology Fort Smith Arkansas 72916
First OC Dermatology Fountain Valley California 92708
University Clinical Trials San Diego California 92123
Horizons Clinical Research Center Denver Colorado 80220
Belleair Research Center Pinellas Park Florida 33781
Dawes Fretzin Dermatology Group Indianapolis Indiana 46256
The Indiana Clinical Trials Center, PC Plainfield Indiana 46168
South Bend Clinic South Bend Indiana 46617
Kansas City Dermatology Overland Park Kansas 66215
Somerset Skin Centre Troy Michigan 48084
Oregon Medical Research Center Portland Oregon 97223
Arlington Research Center, Inc Arlington Texas 76011
Progressive Clinical Research San Antonio Texas 78213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03339999, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 5, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03339999 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →